Jaguar8 commented on a stock · Nov 9, 2024 05:02

NEWS

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics presented preclinical data for FT836, a novel CAR T-cell product candidate targeting MICA/B proteins expressed on cancer cells, at the 2024 SITC Annual Meeting. FT836 incorporates the company's Sword & Shield technology, designed to promote functional persistence without conditioning chemotherapy. The preclinical data demonstrated robust antigen-mediated expansion and durable anti-tumor activity across various solid tumors. The product uniquely targets the α3 domain of MICA/B, stabilizing expression and inducing cytolytic killing of tumor cells. Notably, treatment with chemotherapy or radiation therapy enhanced FT836's cytolytic activity, suggesting potential combination therapy opportunities.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

6748 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

6649

Followers

Following

72K

Visitors